Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma

INTRODUCTION: Checkpoint inhibitors have significantly improved the prognosis of patients with advanced melanoma. These cancer immunotherapy drugs have specific endocrine autoimmune toxicity. We describe a case of an adrenal insufficiency secondary to pembrolizumab, an anti-programmed cell death-1 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Paepegaey, Anne-Cécile, Lheure, Coralie, Ratour, Carole, Lethielleux, Gaëlle, Clerc, Jérome, Bertherat, Jérome, Kramkimel, Nora, Groussin, Lionel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686573/
https://www.ncbi.nlm.nih.gov/pubmed/29264517
http://dx.doi.org/10.1210/js.2017-00170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686573/
https://www.ncbi.nlm.nih.gov/pubmed/29264517
http://dx.doi.org/10.1210/js.2017-00170

Ejemplares similares